The announcement will be applicable for products seen critical to be marketed, with regards to public health.
The Norwegian Medicines Agency encourage MA Holders of products with the following active substances to apply for a Marketing Authorisation in Norway:
|23.10.2018||diazepam||emulsion for injection||5 mg/ml|
|18.04.2018||nifedipin||immediate release tablets/capsules||10 mg|
|05.04.2018||ampicillin||powder for solution for injection/infusion |
500 mg, 1 g and 2 g
The list will be updated as needed